A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells

Autophagy

Volumn 11, Issue 7, 2015, Pages 1161-1178

  Milan, Enrico ^a,b   Perini, Tommaso ^a,b   Resnati, Massimo ^a   Orfanelli, Ugo ^a   Oliva, Laura ^a   Raimondi, Andrea ^a   Cascio, Paolo ^c   Bachi, Angela ^d   Marcatti, Magda ^a   Ciceri, Fabio ^a   Cenci, Simone ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Aggregate; Autophagy; Bortezomib; Endoplasmic reticulum; Multiple myeloma; P62; Plasma cells; Proteasome; Proteasome inhibitors; Proteostasis; SQSTM1; Ubiquitin

Indexed keywords

BORTEZOMIB; DOXORUBICIN; PROTEASOME INHIBITOR; PROTEIN; PROTEIN AGGREGATE; PROTEIN P62; PROTEIN SQSTM1; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; PROTEASOME; PROTEIN BINDING; SEQUESTOSOME 1; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; MULTIPLE MYELOMA CELL LINE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEOMICS; SIGNAL TRANSDUCTION; CELL PROTECTION; DRUG EFFECTS; HOMEOSTASIS; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PROTEIN DEGRADATION; TUMOR CELL LINE; ULTRASTRUCTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPROTECTION; ENDOPLASMIC RETICULUM; HOMEOSTASIS; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN AGGREGATES; PROTEIN BINDING; PROTEOLYSIS; SEQUESTOSOME-1 PROTEIN; UBIQUITINATED PROTEINS;

EID: 84941959385     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2015.1052928     Document Type: Article

References (51)

1. Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J. Cell Biol. 2012; 199: 583-8; PMID: 23148232; http://dx. doi. org/10. 1083/jcb. 201210077.
2. Hideshima T, Anderson KC. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin. Hematol. 2012; 49: 223-27; PMID: 22726545; http://dx. doi. org/10. 1053/j. seminhematol. 2012. 04. 006.
3. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009; 23: 1964-79; PMID: 19741722; http://dx. doi. org/10. 1038/leu. 2009. 173.
4. Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, Lelouard H, Masciarelli S, Mattioli L, Oliva L et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006; 25: 1104-13; PMID: 16498407; http://dx. doi. org/10. 1038/sj. emboj. 7601009.
5. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113: 3040-49; PMID: 19164601; http://dx. doi. org/10. 1182/blood-2008-08-172734.
6. Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012; 92: 921-31; PMID: 22685320; http://dx. doi. org/10. 1189/jlb. 1011497.
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316-19; PMID: 16470606; http://dx. doi. org/10. 1002/cncr. 21740.
8. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557-60; PMID: 17690257; http://dx. doi. org/10. 1182/blood-2006-08-036947.
9. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-70; PMID: 22555973; http://dx. doi. org/10. 1182/blood-2012-03-414359.
10. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011; 10: 2034-42; PMID: 22072815; http://dx. doi. org/10. 1158/1535-7163. MCT-11-0433.
11. Aronson LI, Davies FE. DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 2012; 97: 1119-30; PMID: 22580998; http://dx. doi. org/10. 3324/haematol. 2012. 064923.
12. Cenci S. The proteasome in terminal plasma cell differentiation. Semin Hematol. 2012; 49: 215-22; PMID: 22726544; http://dx. doi. org/10. 1053/j. seminhematol. 2012. 04. 005.
13. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat. Rev. Mol. Cell Biol. 2005; 6: 439-48; PMID: 15928708; http://dx. doi. org/10. 1038/nrm1660.
14. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009; 43: 67-93; PMID: 19653858; http://dx. doi. org/10. 1146/annurev-genet-102808-114910.
15. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147: 728-41; PMID: 22078875; http://dx. doi. org/10. 1016/j. cell. 2011. 10. 026.
16. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol. Cell 2010; 40: 280-93; PMID: 20965422; http://dx. doi. org/10. 1016/j. molcel. 2010. 09. 023.
17. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7: 279-96; PMID: 21189453; http://dx. doi. org/10. 4161/auto. 7. 3. 14487.
18. McLeod IX, Jia W, He YW. The contribution of autophagy to lymphocyte survival and homeostasis. Immunol Rev. 2012; 2: 195-204; http://dx. doi. org/10. 1111/j. 1600-065X. 2012. 01143. x.
19. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol. 2013; 13: 722-37; PMID: 24064518; http://dx. doi. org/10. 1038/nri3532.
20. Pengo N, Scolari M, Oliva L, Milan E, Mainoldi F, Raimondi A, Fagioli C, Merlini A, Mariani E, Pasqualetto E, et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat. Immunol. 2013; 14: 298-305; PMID: 23354484; http://dx. doi. org/10. 1038/ni. 2524.
21. Conway KL, Kuballa P, Khor B, Zhang M, Shi HN, Virgin HW, Xavier RJ. ATG5 regulates plasma cell differentiation. Autophagy 2013; 9: 528-37; PMID: 23327930; http://dx. doi. org/10. 4161/auto. 23484.
22. White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 2012; 12: 401-10; PMID: 22534666; http://dx. doi. org/10. 1038/nrc3262.
23. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-63; PMID: 17568747; http://dx. doi. org/10. 1038/nature 05853.
24. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N. Engl. J. Med. 2013; 368: 651-62; PMID: 23406030; http://dx. doi. org/10. 1056/NEJMra 1205406.
25. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol. Cancer Ther. 2009; 8: 1974-84; PMID: 19509276; http://dx. doi. org/10. 1158/1535-7163. MCT-08-1177.
26. Lamy L, Ngo VN, Emre NCT, Shaffer 3rd AL, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 2013; 23: 435-49; PMID: 23541952; http://dx. doi. org/10. 1016/j. ccr. 2013. 02. 017.
27. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42; PMID: 18191218; http://dx. doi. org/10. 1016/j. cell. 2007. 12. 018.
28. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007; 21: 1367-81; PMID: 17510285; http://dx. doi. org/10. 1101/gad. 1545107.
29. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51-64; PMID: 16843265; http://dx. doi. org/10. 1016/j. ccr. 2006. 06. 001.
30. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, Kroemer G. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009; 16: 87-93; PMID: 18806760; http://dx. doi. org/10. 1038/cdd. 2008. 131.
31. Karantza-Wadsworth, V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, White E. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007; 21: 1621-35; PMID: 17606641; http://dx. doi. org/10. 1101/gad. 1565707.
32. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer. 2008; 8: 51-6; PMID: 18046334; http://dx. doi. org/10. 1038/nrc2274.
33. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat. Rev. Cancer 2004; 4: 966-77; PMID: 15573118; http://dx. doi. org/10. 1038/nrc1505.
34. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007; 67: 1783-92; PMID: 17308121; http://dx. doi. org/10. 1158/0008-5472. CAN-06-2258.
35. Cascio P, Oliva L, Cerruti F, Mariani E, Pasqualetto E, Cenci S, Sitia R. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur. J. Immunol. 2008; 38: 658-67; PMID: 18253932; http://dx. doi. org/10. 1002/eji. 200737743.
36. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 2008; 14: 748-55; PMID: 18542049; http://dx. doi. org/10. 1038/nm1763.
37. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. U S A. 2005; 102: 8567-72; PMID: 15937109; http://dx. doi. org/10. 1073/pnas. 0503221102.
38. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, Itoh M, Tomoda A. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int. J. Oncol. 2011; 38: 643-54; PMID: 21174067.
39. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-89; PMID: 22262760; http://dx. doi. org/10. 1182/blood-2011-10-387365.
40. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014; 10: 1380-90; PMID: 24991834; http://dx. doi. org/10. 4161/auto. 29264.
41. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat. Cell Biol. 2013; 15: 713-20; PMID: 23817233; http://dx. doi. org/10. 1038/ncb2788.
42. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137: 1001-4; PMID: 19524504; http://dx. doi. org/10. 1016/j. cell. 2009. 05. 023.
43. Komatsu M, Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett. 2010; 584: 1374-8; PMID: 20153326; http://dx. doi. org/10. 1016/j. febslet. 2010. 02. 017.
44. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010; 584: 1393-8; PMID: 20040365; http://dx. doi. org/10. 1016/j. febslet. 2009. 12. 047.
45. Rodriguez A, Durán A, Selloum M, Champy MF, Diez-Guerra FJ, Flores JM, Serrano M, Auwerx J, Diaz-Meco MT, Moscat J. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab. 2006; 3: 211-22; PMID: 16517408; http://dx. doi. org/10. 1016/j. cmet. 2006. 01. 011.
46. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372: 155-63; PMID: 18620951; http://dx. doi. org/10. 1016/S0140-6736(08)61035-1.
47. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33: 517-27; PMID: 19250912; http://dx. doi. org/10. 1016/j. molcel. 2009. 01. 021.
48. Komatsu M, Waguri S, Koike M, Sou, YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 131: 1149-63; PMID: 18083104; http://dx. doi. org/10. 1016/j. cell. 2007. 10. 035.
49. Riley BE, Kaiser SE, Shaler TA, Ng, AC, Hara T, Hipp MS, Lage K, Xavier RJ, Ryu KY, Taguchi K, et al. Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection. J. Cell Biol. 2010; 191: 537-52; PMID: 21041446; http://dx. doi. org/10. 1083/jcb. 201005012.
50. Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 Induces Cargo-Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik. Mol Cell Biol. 2014; 34: 3435-49; PMID: 25002530; http://dx. doi. org/10. 1128/MCB. 01383-13.
51. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009; 4: 44-57; PMID: 19131956; http://dx. doi. org/10. 1038/nprot. 2008. 211.